These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 16504676

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone.
    Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M.
    Transplant Proc; 2003 Dec; 35(8):2940-2. PubMed ID: 14697944
    [Abstract] [Full Text] [Related]

  • 4. Renal transplant recipients with coronary artery disease exhibit impairment in fibrinolysis and structural changes in carotid arteries.
    Malyszko J, Malyszko JS, Hryszko T, Brzosko S, Lebkowska U, Mysliwiec M.
    Transpl Int; 2005 Feb; 18(2):256-9. PubMed ID: 15691280
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Fluvastin therapy affects TAFI concentration in kidney transplant recipients.
    Malyszko J, Malyszko JS, Mysliwiec M.
    Transpl Int; 2003 Jan; 16(1):53-7. PubMed ID: 12545342
    [Abstract] [Full Text] [Related]

  • 8. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
    Małyszko J, Tymcio J.
    Pol Arch Med Wewn; 2008 Jan; 118(1-2):36-41. PubMed ID: 18405171
    [Abstract] [Full Text] [Related]

  • 9. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
    Małyszko J, Łebkowska U, Małyszko JS, Myśliwiec M.
    Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Possible relations between thyroid function, endothelium, and kidney and liver function in kidney allograft recipients.
    Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M.
    Transplant Proc; 2006 Dec; 38(10):3509-13. PubMed ID: 17175317
    [Abstract] [Full Text] [Related]

  • 15. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
    Małyszko J, Małyszko JS, Hryszko T, Pawlak K, Myśliwiec M.
    Am J Nephrol; 2004 Dec; 24(6):624-9. PubMed ID: 15627717
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 19. Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis?
    Bouma BN, Mosnier LO.
    Ann Med; 2006 Sep; 38(6):378-88. PubMed ID: 17008302
    [Abstract] [Full Text] [Related]

  • 20. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
    Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN.
    Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.